|
|
|
| home > white papers > Contemporary Issues in Comparator Trial Supply - Clinigen CTS |
|
|
 WHITE PAPERS |
|
Clinigen CTS
|
|
Contemporary Issues in Comparator Trial Supply
|
|
The past five years has seen a great deal of change in clinical trial management. As the bio-pharma industry looks to speed development times and consolidate new product pipelines, in a quest for improved R&D efficiency, it is no surprise that phase III trial design, planning and execution in particular has been under great scrutiny. Cost of comparator agents alone has escalated to up to $100m per year for top companies (and is predicted to grow further). Consequently innovative approaches, novel project planning and increasingly close partnerships with specialist outsourcing service providers have come to the fore.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022
Stockley Park, UK – 3 November 2022 – Gilead Sciences, Inc. and
Kite, a Gilead Company, will support 30 data presentations, including
seven oral presentations in large B-cell lymphoma (LBCL) and two oral
presentations on investigator-sponsored studies in acute myeloid
leukaemia (AML), during the 64th Annual American Society of Hematology
(ASH) Annual Meeting (10-13 December).
More info >> |
|
 |
White Papers |
 |
|
Translating Cancer Genomics Into A Personalised Approach For Cancer Patients
PRA Health Sciences (PRA)
Over the past few decades, the approach to prevention, diagnosis and treatment of cancer has radically shifted from organ-based to morphology-based and most recently, to genetics-based. Personalized or precision medicine (tailoring a treatment for a patient’s particular disease at a precise time point) is being performed every day at different levels in the clinical setting.
More info >> |
|
|
|
